Table 1. Baseline and follow-up study sample demographic, laboratory and clinical characteristics.
| Baseline | Follow-up | p | |
|---|---|---|---|
| Age | 55.08±7.53 | 56.74±7.61 | <.0001 |
| Education | 14.06±2.75 | 14.11 ± 3.20 | .85 |
| Gender (count) | 79 males / 1 females | - | |
| Ethnicity (% Anglo-Australian) | 98.7% | - | |
| Australian standardized Predicted WAIS-III VIQ | 108.97±7.22 | - | |
| HIV Risk groups (%MSM) | 86.2% | - | |
| HAND % | 53.7% | - | |
| ANI / MND / HAD % | 36.2% / 10.0% / 7.5% | - | |
| History of HAND % | 15.0% | - | |
| Median Nadir CD4-T cell count (cells/mL) | 194 | - | |
| Median Current CD4-T cell count (cells/mL) | 556 | 614 | <.0001 |
| Plasma HIV RNA <50 cp/mL | 97.5% | 87.5% | .08 3 |
| Always undetectable % (vs. not always) | - | 85% | |
| CSF HIV RNA <50 cp/mL (N = 34) | 97% | - | |
| Median HIV duration (years) | 19.1 | - | |
| AIDS (CDC 1993) 1 | 67.5% | No new CDC C | |
| Median Current cART duration (months) 2 | 29 | 37 | |
| ART treated during 1st year of HIV infection | 20.0% | - | |
| Log(n) HIVDNA in PBMCs | 5.21 ± 1.42 | 5.12 ± 1.40 | .45 4 |
Mean ± SD, otherwise indicated; HAND: HIV-associated neurocognitive disorder; ANI: Asymptomatic neurocognitive impairment; MND; Mild Neurocognitive Disorder; HAD: HIV-associated dementia
1No new AIDS defining Illness, 1 single case had a CD4 dropping below 200 cp/mL
288.7% did not change their cART between baseline and follow-up. There was a significant difference between those who changed cART and those who did not in their plasma viral load suppression at follow-up: changed and detectable = 33.3%; did not change and detectable = 9.8%; p<.05.
3Log10 Plasma HIV RNA were compared using Wilcoxon Signed Rank Test
4Pearson correlation between baseline and follow-up Log(n) is. 73.